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Summary
Objective: This study investigated the in-vitro effects of a crystalline glucosamine sulfate (GS) preparation on DNA
synthesis and on proteoglycan (PG) and type II collagen (coll II) production by human articular chondrocytes isolated
from human osteoarthritic articular cartilage in a 3-dimensional culture system for 4, 8, and 12 days.
Materials and Methods: Human articular chondrocytes from osteoarthritic femoral heads were isolated from their
matrix by collagenase digestion and then cultured in suspension. Under constant agitation, cells aggregated and
formed a cluster within a few days. The effects of GS (1–100 mg/ml) on chondrocytes were determined by quantifying
DNA synthesis (by measurement of [3H]-thymidine uptake) as well as PG and coll II production using
radioimmunoassays (RIAs) specific for coll II and to human human cartilage PG. Cross-reaction with GS in the RIAs
was not detected. Moreover, PG size distribution was determined by exclusion chromatography under associative
conditions to determine the association of PG monomers with hyaluronic acid (HA) to form large molecular weight
PG aggregates.
Results: Under the above conditions, PG production in culture media and chondrocyte clusters was increased by
GS (10–100 mg/ml). DNA synthesis and coll II production were not modified by GS. In addition, GS did not modify the
physico-chemical form of PG produced by cells during culture.
Conclusions: Glucosamine sulfate did not affect DNA synthesis nor coll II production but caused a statistically
significant stimulation of PG production by chondrocytes from human osteoarthritic cartilage cultured for up to 12
days in 3-dimensional cultures.
Keywords: Glucosamine sulfate, Human chondrocytes, Chondrocyte, Glycosaminoglycan, Proteoglycan, Osteoar-
thritis.
Introduction
Osteoarthritis (OA), a common disease that
induces pain and impairs quality of life [1], is
caused by a degenerative process primarily
affecting articular cartilage. Articular cartilage is
a connective tissue composed of chondrocytes
embedded in a matrix essentially constituted by
proteoglycans (PGs) and type II collagen (coll II)
[2]. Cartilage is subject to anabolic processes
(chondroformation) and catabolic processes (chon-
droresorption). In healthy chondrocytes, a dy-
namic equilibrium of these processes is
maintained. However, articular diseases such as
OA are characterized by a disturbance in this
equilibrium. Catabolic processes exceed anabolic
processes, leading to a net decrease of matrix [3].
Much research into the causes of this net decrease
has focused on hormones, growth factors, precur-
sors of matrix elements, and cytokines, such as
interleukin-1 (IL-1) [4].
Current OA treatment includes physical, phar-
macological, and surgical approaches. Pharmaco-
logical treatments have been divided into three
categories [5], (1) analgesics and non steroidal
anti-inflammatory drugs (NSAIDs); (2) symp-
tomatic slow-acting drugs for osteoarthritis; and
(3) chondroprotective or disease modifying drugs.
The agent investigated in this study, glucosamine
sulfate (GS), falls under the second category.
GS is an amino-monosaccharide and one of the
basic components of the disaccharide units of
articular cartilage glycosaminoglycans. Recent
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attention about the symptomatic relief afforded by
GS for OA has spurred new basic scientific
investigation into the agent’s effects on cartilage.
Clinically, GS has been developed according to the
international Osteoarthritis Research Society and
GREES clinical trial guidelines [6]. A comparative
study has demonstrated that GS relieves knee OA
symptoms to an extent similar to that of NSAIDs
[7].
Research from as early as 1971 demonstrated
that exogenous glucosamine increased the syn-
thesis of glycosaminoglycans in cartilage cultures
[8–10]. In vivo, animal pharmacokinetic studies
have shown that radiolabeled GS was selectively
incorporated into articular cartilage after systemic
administration [11].
The aim of this study was to assess in vitro the
effects of GS on human osteoarthritic articular
chondrocytes maintained for as long as 12 days in
a 3-dimensional culture. After a few days of culture
in suspension, human chondrocytes (obtained from
osteoarthritic femoral heads) aggregate and form a
cluster. In 3-dimensional culture, chondrocytes
maintain their differentiated phenotype both
morphologically (round shape, surrounded by a
newly synthesized matrix) and biosynthetically (by
production of a matrix composed of cartilage PGs
and coll II) [12]. Chondroformation was studied by
measuring DNA synthesis and the production of
specific components of the cartilage matrix (PGs
and coll II) in the culture media (CM) and in the
chondrocyte clusters (CCs).
Materials and methods
culture of human OA chondrocytes
Using the method of Bassleer et al. [12], cartilage
was taken from three human osteoarthritic
femoral heads (mean age: 72 years) immediately
after surgery for total hip prosthesis. Macroscopi-
cally, the collected cartilage was not altered, but
histological study of representative samples
showed typical osteoarthritic changes such as the
presence of chondrocyte clusters, loss of metachro-
masia, and fibrillation. Cartilage was digested with
1 mg/ml clostridial collagenase (Boehringer
Mannheim, GmbH, Germany) in a carbonate–bi-
carbonate buffer (120 mM CaCl2, 5 mM KH2PO4,
25 mM NaHCO3, 2 mM glucose and 30 mM HEPES,
pH 7.4) for 24 h. Chondrocyte viability was
examined by trypan blue exclusion. After six
successive washings and centrifugations, the cells
were suspended in glass flasks (Sovirel flask) at a
density of 106 cells/2 ml culture medium. The
culture medium was DMEM-Dulbecco’s Modifi-
cation of Eagle’s Medium (ICN, Brussels, Belgium)
containing Ultroser G 1% (Gibco, Ghent, Belgium)
and 50 mg ascorbate/ml. Cultures were maintained
on a gyratory shaker at 37° C in a 95% air–5% CO2
atmosphere.
treatment of chondrocyte cultures with GS
The preparation of crystalline GS (MW:573.30)
(Dona8, Rotta Research Laboratorium, Monza,
Italy) consists of two molecules of glucosamine
combined with one molecule of sulfate. Crystalline
GS contains 79.6% (w/w) GS (M.W. 456.42), i.e.
62.5% GS base (M.W. 179.17). Crystalline GS
(0.56 · 10 - 5, 5.6 · 10 - 5, 5.6 · 10 - 4 M, i.e. 0, 1, 10,
100 mg/ml GS base) was present in the culture
media (CM) for 4, 8, or 12 days; CM was renewed
each 4 days. In other experiments, chondrocytes
were further cultured in the absence of GS from
days 12 to 16. These periods of culture are based on
previous experiments demonstrating varied effects
of GS on chondrocyte biosynthetic activities. For
each concentration of GS and for the correspond-
ing controls, four flasks were used; each flask
contained a chondrocyte cluster obtained from 106
isolated chondrocytes.
PG and coll II produced by human chondrocytes
were assayed in conditioned CM and CCs
employing specific radioimmunoassays (RIA).
There was no cross-reaction between PG syn-
thesized by the chondrocytes and GS present in the
cultures, even at 10 mg/ml, indicating that the RIA
did not detect GS epitopes. At the end of the
various culture periods, the CCs were prepared for
fluorimetric DNA assay, for measurements of
[3H]-thymidine incorporation and for RIAs as
follows: CCs were washed three times with
phosphate-buffered saline (PBS: PO4 0.05 M, NaCl
0.15 M, pH 7.4) and homogenized in PBS contain-
ing a mixture of protease inhibitors [13], sodium
azide 6.7 · 10- 3 M, and superoxide dismutase
(200 U/ml) by ultrasonic dissociation (power:
200 W/cm2) for two 30-sec intervals at 4° C. The
mixture of protease inhibitors included 0.1 M
6-amino-hexanoic acid, 0.001 M EDTA, 0.05 M
benzamidine chlorhydrate, and 5 · 10- 8 M trypsin
inhibitor.
analysis of [3H]-thymidine incorporation
Human chondrocytes were incubated in media
containing GS (0–100 mg/ml) during the entire
culture duration (4, 8, or 12 days) and 2 mCi/ml
(5 Ci/mM) methyl [3H]-thymidine (Amersham,
Brussels, Belgium) during the last 24 h of the
experiment (i.e. from day 3–4, from day 7–8, or from
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day 11–12). In order to remove non-incorporated
[3H]-thymidine, the CCs were washed repeatedly
with PBS containing unlabeled thymidine (100 mg/
ml) (3 · 20 min) and transferred to PBS containing
protease inhibitors as described above. At that
point, CCs were homogenized by ultrasonic
dissociation for 2 · 30 seconds at 4 ° C (power
200 W/cm2) in the same PBS buffer described
above. Incorporated radioactivity was measured
with a beta-counter (Packard tri-Carb) as de-
scribed previously [14, 15].
determination of PG content in CM and CC
PGs released into CM or present in the CC were
radioimmunologically assayed as described in
detail by Gysen and Franchimont [16]. For the
assay, human cartilage PGs were extracted
according to the methods of Roughley et al. [17]
and Bayliss and Venn [18]. The human cartilage
PG antiserum was raised in rabbits as described by
Vaitukaitis et al. [19]. The incubation solution
consisted of 0.1 ml tracer solution (15 000–
20 000 cpm 125I-PG labeled by the chloramine-T
method) [20]; 0.1 ml anti-PG antiserum diluted
1:5000 in PBS (as above) with 5 g/L BSA
(incubation buffer); and 0.2 ml serial dilutions of
either conditioned CM, cluster extracts, or
unlabelled antigen ranging from 0.1 to 500 ng/tube
(reference curve). After 4 days at 4° C, the labeled
PG-antibody complexes were separated by double
precipitation [21]. The analytical sensitivity of the
RIA was 0.6 ng/tube, and intra- and inter-assay
coefficients of variation were less than 10% and
20%, respectively, along the linear range of the
curve. Separate glycosaminoglycan digestion ex-
periments and the absence of cross-reactivity with
isolated glycosaminoglycans indicated that the
antibodies were specifically directed against the
antigenic determinants of the PG core protein.
There was no interference of coll II, fibronectin,
chondroitin sulfate, GS, or hyaluronic acid with
the assay [16].
gel filtration chromatography of PGs
produced by chondrocytes
The PGs in CM and in CCs were chromato-
graphed on a Sepharose Cl-2B column. CM were
directly chromatographed on the column. PGs
were extracted from CC after various culture
durations (4, 8 or 12 days) employing 4M-guanidine
HCl, (0.2 M sodium acetate, pH 5.8), containing
protease inhibitors [13], and maintained for 24 h at
4° C. The cluster extracts were then dialyzed
against distilled water and 0.5 M sodium acetate,
pH 7.0. The extracts employed for chromatographic
analyses were not submitted to sonication. For
analytical purposes, a column (0.8 · 60 cm) was
packed with Sepharose Cl-2B. The column was
equilibrated with 0.05 M sodium acetate, pH 7.0,
containing the protease inhibitors previously
described [13]. Flow rate was 5 ml/hour and 1 ml
fractions were collected. PG aggregates
(MW q 20.106) and [3H]-methyl thymidine were
used to determine the excluded (Vo) and total (Vs)
column volumes, respectively. PG immunoreactiv-
ity was determined in each elution fraction [16].
coll II assay
Coll II was assayed radioimmunologically as
described by Henrotin et al. [22]. In this assay coll
II extracted from human articular cartilage [23] is
used as immunogen, tracer, and reference prep-
aration. A polyclonal antiserum was obtained in
guinea pigs. The sequential assay first utilized a
mixture of 0.1 ml of incubation buffer (PBS; 0.3 M
NaCl, pH 7.4), 0.1 ml of coll II reference solution (1
to 500 ng), CM or cluster extracts, and 0.1 ml
guinea pig antiserum (1:5000). Then 0.1 ml 125I-
labelled coll II, which was iodinated using the
Iodogen method [24] and diluted to obtain
20 000 cpm, was added. After 18 h at 4 ° C, the
labelled PG-antibody complexes were separated by
double precipitation [21]. Cartilage PG,
fibronectin, laminin, type I or type III collagen, GS
and glycosaminoglycans did not interfere in the
assay. The assay’s detection limit was 20 ng/ml.
Intra- and inter-assay coefficients of variation were
8 and 15%, respectively.
DNA assay
Cluster DNA content was assayed according to
the fluorimetric method of Labarca and Paigen
[25]. This method is based on the principle of a
fluorescent emission when the reactive
fluorochrome–bis–benzimidazol (Calbiochem-
Behring, La Jolla, CA, USA; Hoechst dye 33258) is
bound to DNA.
statistical analysis
The results were expressed as PG amounts in CM
or CC per mg of DNA. Total PG and coll II
production was also calculated by adding the
amounts present in CM and in the corresponding
clusters. The mean 2 SD of each variable ([3H]-
thymidine incorporation, and coll II and PG
amounts in CM or in CC) was calculated.
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Table I
PG content of culture media from control or GS treated chondrocytes
Culture period (days) Control GS (1 mg/ml) GS (10 mg/ml) GS (100 mg/ml)
0–4 19.5 2 2.0 22.6 2 0.6 27.3 2 0.9* 30.1 2 2.6*
4–8 3.7 2 0.1 3.7 2 0.5 5.0 2 0.4* 5.8 2 0.2*
8–12 1.0 2 0.1 0.9 2 0.1 1.3 2 0.1* 1.5 2 0.1*
Isolated human OA articular cartilage chondrocytes were cultured as described in Materials and Methods[ The
amounts of PG were measured in culture medium "mg:mg DNA 85 h# for each period of culture in samples from
chondrocytes incubated without GS "controls# or in presence of GS "0\ 09\ 099 mg:ml# "]PQ 9[914 v control^
U!test from MannWhitney#[
Comparison of mean values was performed using
the Mann–Whitney U-test.
Results
[3H]-thymidine incorporation
DNA synthesis, as measured by [3H]-thymidine
uptake, was similar in the four groups examined
(controls, 1, 10 or 100 mg GS/ml).
PG and coll II production
Tables I and II show the amounts of PG
measured in CM and in CC, as a function of culture
duration. In absence of treatment, these results are
similar to the results obtained with human
osteoarthritic chondrocytes cultured under similar
conditions in previous studies [12]. GS (10 or
100 mg/ml) induced a significant increase of the
amount of PG measured in CM (Figure 1) and in
CC (Figure 2) at each period of the culture. The
total PG production (sum of the amounts of PG
measured in CM and in the corresponding cluster)
after 12 days of culture demonstrated that GS
increased total PG production significantly (38 and
54% for 10 and 100 mg/ml GS, respectively).
However, 96% of the newly synthesized PG was
released in the CM while only 4% remained in CC.
When cells were cultured during the first 12 days
in the presence of GS (10 or 100 mg/ml) and in the
absence of GS during the following four days, a
significant increase of the amount of PG in CC and
CM continued to be observed in cultures pre-
viously incubated with 100 mg of GS, as compared
to untreated controls (Table III). Comparisons
between cells treated with GS for 12 days with
continued culture through 16 days without GS and
untreated controls demonstrated a significant
increase in PGs of the cells treated with GS until
day 12 during days 12–16 (following removal of GS
at the day 12) as shown in Table III. GS did not
affect coll II production in CM and CC, as
compared to untreated controls.
gel filtration chromatography of PG from CM
or CC
Chromatographic profiles of PG extracted from
CC after 4, 8, or 12 days of culture in the presence
of 0, 10, or 100 mg GS/ml performed under
associative conditions showed that GS (10 or
100 mg/ml) did not modify the PG physico-chemical
forms in CC, as compared to untreated controls
(data not shown). Similarly, GS (10 or 100 mg/ml)
did not affect the PG physico-chemical forms in
CM, as compared to untreated controls (data not
shown). In samples from both control and
GS-treated cultures the majority of PG appeared in
the region of intact PG complexes and PG
monomers. Measurements of PG content in the
chromatographic fractions corroborated the re-
sults shown in Tables I and II since greater
amounts of PG were present in the fractions
obtained with equal volume samples from GS-
treated cultures compared to untreated cultures
(data not shown).
Table II
PG content of chondrocyte clusters from control and GS treated cultures
Period of culture (days) Control GS (1 mg/ml) GS (10 mg/ml) GS (100 mg/ml)
0–4 394 2 42 420 2 56 513 2 52* 558 2 4*
0–8 504 2 57 584 2 99 660 2 69* 814 2 10*
0–12 1050 2 64 1100 2 49 1335 2 97* 1481 2 12*
Isolated human OA articular cartilage chondrocytes were incubated as described in Materials and Methods[
The amounts of PG were measured in chondrocyte clusters "ng:mg DNA# for each period of culture\ in samples
from chondrocytes incubated without GS "controls# or in presence of GS "0\ 09\ 099 mg:ml# "]PQ 9[914 v
control^ U!test from MannWhitney#[
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Fig. 1. Total amount of PG measured in culture medium
(CM)(mg/mg DNA) after 12 days of culture in chondro-
cytes cultured under control conditions or in the
presence of GS (1, 10, 100 mg/ml). Different letters (a $ b)
indicate significantly different values (P Q 0.05).
Thus the stimulatory effect persisted at least 4 days
after the withdrawal of GS.
The PG cluster content at day 12 was approxi-
mately 1 mg/mg DNA. The total PG production in
CM (sum of the PG amounts measured in CM
during the 12 days of culture) was 2 25-fold the PG
amounts measured within the clusters. Indeed,
only 4% of PG produced by chondrocytes remained
in the clusters, surrounding the cells. This may be
explained by the fact that a large cluster surface
was in direct contact with the nutrient medium
(2 ml). Moreover, the cluster volume (2–3 mg fresh
weight/mg DNA) was substantially smaller than
the 2 ml CM volume.
Our results showing a GS-induced increase of PG
production indicate that GS caused a positive
balance between PG synthesis and PG degra-
dation. Several former experiments have reported
that GS was able to stimulate the 35SO4 uptake
(marker of GAG synthesis) in vitro [8, 9] and ex vivo
[10]. This study suggests that GS stimulates PG
core protein production, because in the RIA the PG
antiserum is directed against the human cartilage
PG core protein [16].
GS appears to affect specifically the synthesis of
monomeric PG capable of assembling into large
molecular weight PG aggregates, since lower size
PG identified by gel filtration on Sepharose Cl-2B
only represent a minor portion of the total
immunoreactive PG. These findings are supported
by the recent work of Jimenez et al. [26], which
demonstrated that in normal human adult chon-
drocytes in vitro, GS increases aggrecan protein
mRNA. In addition, Hellio et al. [27] recently
observed that GS induced an increase of protein
synthesis in human OA chondrocytes in vitro.
Based on these results, we suggest that GS acts
through an increase of sulfated GAG synthesis,
which, in turn, induces PG core protein production
by human chondrocytes. Such an explanation is
supported by the fact that GS stimulates 35SO4
uptakes in rat articular cartilage in vitro. Similar
results were also achieved in ex vivo experiments
following treatment of animals for 14 days with
oral GS [9, 28]. Analyzed together, these exper-
iments suggest that GS is able to stimulate GAG
production and the synthesis of PG.
Sulfate is an essential substrate in the synthesis
of cartilage GAG and its availability is a limiting
factor in this synthesis [29–33]. In other experimen-
tal conditions, in vitro studies have demonstrated
that GS is a substrate for GAG synthesis. For
instance, Roden et al. [34], showed that GS
stimulates the 35SO4 uptake by cartilage while it
inhibits the uptake of labeled glucose (which is
usually used for these syntheses). A possible
Discussion
This study demonstrates that treatment of
human articular cartilage chondrocytes with GS
(10–100 mg/ml) in vitro induces a significant
increase of PG amounts measured in clusters and
in CM. Moreover, when GS (100 mg/ml) was added
to the chondrocytes during the first 12 days of
culture and removed from the CM for days 12–16,
a significant increase of the amount of PG in CM
and in CC was still observed at day 16 of culture.
Fig. 2. Amount of PG measured in chondrocyte clusters
(CC) (ng/mg DNA) after 12 days of culture in
chondrocytes cultured under control conditions or in
presence of GS (1, 10, 100 mg/ml). Different letters (a $ b)
indicate significantly different values (P Q 0.05).
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Table III
Total PG content of chondrocyte cultures following withdrawal of GS
Previous treatment with GS from day 0–12 PG in CM from day 12–
16 (ng/mg DNA) PG in CC at day 16 (ng/mg DNA)
0 mg/ml 420 2 60 784 2 89
10 mg/ml 440 2 50 796 2 78
100 mg/ml 580 2 70* 985 2 113*
The conditions of culture were as described in Materials and Methods[ The amounts of PG
were measured in culture medium "CM# and in chondrocyte clusters "CC# "ng:mg DNA#
between day 01 and day 05 in control cultures and in cultures previously treated from day 9
to day 01 with GS "09\ 099 mg:ml#[
"]PQ 9[914 v control^ U!test from MannWhitney#[
explanation is that GS enters a metabolic pathway
that is more favorable for the chondrocytes and
requires less energy than the one starting from
glucose. GS may be then transformed into its
derivatives N-acetyl-glucosamine or galac-
tosamine, which are precursors of hyaluronic acid,
chondroitin sulfate and keratan sulfate, the
cartilage GAG [35]. GS is likely to be incorporated
in the cytoplasm of the chondrocytes, integrated
into GAG and PG and deposited in the matrix. This
metabolic process was illustrated previously using
[14C]-glucosamine incorporation in cartilage tissue,
as well as in human chondrocytes in three-dimen-
sional culture [12].
Many factors and substances modulate the
biosynthesis and the ultimate physico-chemical
forms of the PG macromolecule, thus altering the
physical properties of articular cartilage [36–42].
Although there were no detectable differences
between control or GS treated samples, Sepharose
Cl-2B profiles of PG in CM and PG extracted from
CC demonstrate that there is more immuno-
reactive material corresponding to the complexes
PG-HA-link protein in CC than in CM. Conversely,
there was a greater proportion of small PG and PG
fragments in CM than in CC. These data indicate
that PGs in clusters are functionally capable of
binding to HA (hyaluronic acid) stabilized by link
protein, whereas PGs in CM represent either
molecules with incomplete structures (without
HA-binding region) or complexes of small PG
bound to HA. Furthermore, our experiment
showed that PG extracted from the matrix of
human chondrocyte clusters are comparable to
native cartilage PG in terms of molecular size and
ability to participate in complex formation with
HA.
In this work, we found that GS did not affect cell
proliferation nor coll II production by human
chondrocytes cultivated in clusters. Our results
agree with other studies showing that GS did not
change the level of production of type II
procollagen in another type of culture [26].
The stimulatory effects of GS on PG production
in vitro are supported by a favorable pharmacoki-
netic behavior. It was, in fact, demonstrated that
after systemic administration (oral or parenteral)
of uniformly labeled [14C]-GS, to rats and dogs the
compound appeared in plasma and then rapidly
diffused into several organs and tissues, including
the articular cartilage [43–44]. Our results,
showing a stimulatory effect of GS on the
biosynthetic activity of human chondrocytes are
also in agreement with previous experiments
reporting that GS exerts a protective action in
animal models of experimental OA [45]; that GS
counteracts the metabolic and morphologic dam-
ages induced on chondrocytes by dexamethasone
[46] or on cartilage by some NSAIDs [11]; and that
its medium- or long-term effect in patients with
knee or spine OA compares favorably to that of
NSAIDs [47–50].
In conclusion, the GS-induced increase of PG
production by OA chondrocytes in vitro may
represent a step towards normalization of impaired
chondrocyte metabolism that is characteristic of
OA and thus a step to cartilage repair.
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